First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Delnomdedieu, Marielle ^a   Duvvuri, Sridhar ^a   Li, David Jianjun ^a   Atassi, Nazem ^b   Lu, Ming ^c   Brashear, H Robert ^c   Liu, Enchi ^c   Ness, Seth ^c   Kupiec, James W ^a  

^a PFIZER INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Janssen R and D ^*  (United States)

Author keywords

Alzheimer's disease; ARIA; Humans; Immunotherapy; Monoclonal antibody; Pharmacokinetics; Safety

Indexed keywords

AAB 003; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY;

ADULT; AGED; ALZHEIMER DISEASE; ANXIETY; ARTICLE; BACKACHE; CEREBROSPINAL FLUID; CLINICAL TRIAL; CONTUSION; DECREASED APPETITE; DIZZINESS; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; GAIT DISORDER; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; POLLAKISURIA; PRIORITY JOURNAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; VERY ELDERLY; VOMITING; WEIGHT GAIN; BLOOD; BRAIN EDEMA; CHEMICALLY INDUCED; CONTROLLED STUDY; DOSE RESPONSE; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; BIOMARKERS; BRAIN EDEMA; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX;

EID: 84966388958     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0177-y     Document Type: Article

References (17)

1. Salloway S, Sperling R, Fox N, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370:322-33.
2. Doody R, Thomas R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimers disease. N Engl J Med. 2014;370:311-21.
3. Blennow K, Hampel H, Zetterberg H. Biomarkers in amyloid-beta immunotherapy trials in Alzheimer's Disease. Neuropsychopharmacology. 2014;39:189-201.
4. Prins N, Scheltens P. Treating Alzheimer's disease with monoclonal antibodies: current status and outlook for the future. Alzheimers Res Ther. 2013;5:56.
5. Panza F, Solfrizzi V, Imbimbo BP, Tortelli R, Santamato A, Logroscino G. Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014;10:405-19.
6. Black RS, Sperling RA, Safirstein B, Motter RN, Pallay A, Nichols A, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24:198-203.
7. Sperling R, Bronen R, Greenberg S, Sorensen AG, Salloway S, Gass A, et al. Three cases of apparent vasogenic edema (VE) from a phase 2 clinical trial of the gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate AD. Alzheimers Dement. 2011;7:S377.
8. Doody R. Results from independent analyses of the EXPEDITION (solanezumab) study data conducted by the Alzheimer's Disease Cooperative Study (ADCS). In: Proceedings of the Annual Meeting of the American Neurological Association. Boston, Massachusetts; 2012.
9. Ostrowitzki S, Deptula D, Thurfjell L, Barkhof F, Bohrmann B, Brooks D, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69:198-207.
10. Sperling RA, Jack Jr CR, Black SE, Frosch M, Greenberg S, Hymans B, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement. 2011;7:367-85.
11. Sperling R, Salloway S, Brooks D, Tampieri D, Barakos J, Fox N. Amyloid-related imaging abnormalities (ARIA) in Alzheimer's disease patients treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11:241-9.
12. Carlson C, Estergard W, Oh J, Suhy J, Jack C, Siemers E, et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers Dement. 2011;7:396-401.
13. Bacskai BJ, Kajdasz ST, McLellan ME, Games D, Seubert P, Schenk D, et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci. 2002;22:7873-8.
14. Tamura Y, Hamajima K, Matsui K, Yanoma S, Narita M, Tajima N, et al. The F(ab)'2 fragment of an Abeta-specific monoclonal antibody reduces Abeta deposits in the brain. Neurobiol Dis. 2005;20:541-9.
15. Ji Y, Li Y, Bekele B. "Practical Dose-finding in Phase I Clinical Trials Based on Toxicity Probability Intervals. Clin Trials. 2007;4(3):235-44.
16. Salloway S, Sperling R, Gilman S, Fox N, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer's disease. Neurology. 2009;73:2060-70.
17. Siemers E, Friedrich S, Dean R, et al. Safety and changes in plasma cerebrospinal fluid amyloid ß monoclonal antibody in subjects with Alzheimer's disease. Clinical Neuropharmacology. 2010;3:67-73.